Lipid Management That’s on Target
The Esperion team leverages its experience and understanding of cholesterol biosynthesis to develop and commercialize once-daily, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for patients with elevated LDL-C who are inadequately treated with current lipid-modifying therapies.
In the past, cholesterol drug discovery and development efforts were aimed primarily at therapies designed to inhibit a key enzyme on the cholesterol biosynthesis pathway, HMG-CoA reductase. Esperion’s founder, Dr. Roger Newton, co-discovered and helped lead the development of the most successful drug to inhibit HMG-CoA reductase, Lipitor® (atorvastatin calcium).
Esperion’s approach to cholesterol regulation has enabled it to develop new complementary, non-statin, once-daily, oral small molecule therapies that target another key enzyme on the cholesterol biosynthesis pathway, ATP-citrate lyase (ACL), upstream of HMG-CoA reductase.